<?xml version="1.0" encoding="UTF-8"?>
<p id="Par103">DLT should be evaluated from the initial administration of this drug until administration on the first day of administration in Cycle 2. In subjects in whom the appearance of toxicity made this-drug administration in Cycle 2 impossible, and treatment was discontinued, DLT must be evaluated until safety follow-up.</p>
